Oncolytics Biotech (ONCY) to Release Earnings on Thursday

Key Points

• Oncolytics Biotech is set to release its Q2 2025 earnings on August 7th, with analysts predicting an earnings per share of ($0.10) for the quarter.
• The company recently reported ($0.06) earnings per share for Q1 2025, surpassing expectations by $0.03, and has a market cap of $101.31 million.
• Analysts have a consensus rating of "Moderate Buy" for Oncolytics Biotech, with a target price of $4.33, and one firm has set a price target as high as $5.00.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.03. On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncolytics Biotech Price Performance

Shares of NASDAQ:ONCY traded down $0.03 during mid-day trading on Friday, reaching $0.99. 537,614 shares of the company were exchanged, compared to its average volume of 1,311,766. The firm's 50-day simple moving average is $0.80 and its 200 day simple moving average is $0.69. Oncolytics Biotech has a 1 year low of $0.33 and a 1 year high of $1.53. The firm has a market cap of $96.44 million, a price-to-earnings ratio of -3.41 and a beta of 1.09.

Analysts Set New Price Targets

Several equities analysts have commented on ONCY shares. HC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Oncolytics Biotech in a research report on Wednesday, May 21st. Jones Trading reiterated a "hold" rating on shares of Oncolytics Biotech in a research note on Friday, May 16th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $4.33.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.